David Huffman, MD
Endocrinology, Diabetes & Metabolism · Chattanooga, TNNPI 1811101256
Payments from drug & device makers
Across 4,340 payments — averaging $562.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$899K
- Novo Nordisk AS$897K
- Insulet Corporation$165K
- Sequel Med Tech, LLC$151K
- Novo Nordisk$89K
- AbbVie$79K
- plus $162K from 54 others
Across 7 payments — averaging $9925.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$69K
- Novo Nordisk AS$50
- Novo Nordisk$48
What the payments were for
- Consulting fees$9,1036%
- Speaking & faculty fees$122,69475%
- Travel & lodging$5,6103%
- Food & beverage$25,26416%
- Education$1440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$38,752
- Ozempic$21,240
- Tresiba$16,348
- INVOKANA$14,157
- Omnipod$10,172
- Kerendia$8,326
- t:slim X2 insulin pump$7,500
- STEGLATRO$5,737
- CeQur Simplicity$729
- MINIMED 780G$656
- ENROUTE Transcarotid Neuroprotection System$274
- FreeStyle Libre 2$168
- HawkOne$167
- ENROUTE Transcarotid Stent$137
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$137
- TWIIST$137
- RECORLEV$127
- TEPEZZA$123
- AFREZZA$123
- Korlym$105
How this compares
$2,442,203 in reported general payments places this provider in the 95th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 339 | $424,473 |
| OzempicSemaglutide | 178 | $322,659 |
| JardianceEmpagliflozin | 144 | $157,040 |
| Tresiba Flextouch U-200Insulin Degludec | 71 | $133,417 |
| Tresiba Flextouch U-100Insulin Degludec | 99 | $89,080 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $85,943 |
| Humalog Kwikpen U-200Insulin Lispro | 13 | $76,317 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 49 | $75,809 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 48 | $67,136 |
| FarxigaDapagliflozin Propanediol | 68 | $65,643 |
| Novolog FlexpenInsulin Aspart | 72 | $48,063 |
| TrulicityDulaglutide | 19 | $35,314 |
| NovologInsulin Aspart | 50 | $30,484 |
| FiaspInsulin Aspart (Niacinamide) | 11 | $30,320 |
| Humulin R U-500Insulin Regular, Human | 12 | $29,318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $7,887 | $471,578378 claims |
| Novo NordiskOzempic, Novolog, Fiasp | $89,142 | $383,462239 claims |
| Boehringer IngelheimJardiance, Glyxambi | $733 | $178,451167 claims |
| AstraZenecaFarxiga, Byetta | $632 | $76,51181 claims |
| AbbVieSynthroid, Armour Thyroid | $78,834 | $38,981391 claims |
| MerckJanuvia | $6,006 | $25,13133 claims |
| Johnson & JohnsonInvokana | $14,799 | $13,82312 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $413 | $3,756383 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $43 | $2,75941 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Chattanooga
- Asma KhanChattanooga$17K
- Abhinaya JawaharChattanooga$8K
- Stephen SharpNashville$25.9M
- Lisa UsdanMemphis$14.3M
- Kathryn DahirNashville$11M
- Pedro VelasquezMemphis$2.4M
- Craig WierumNashville$1.7M
- Alan CohenMemphis$1.5M
- Terri JerkinsNashville$1.2M
- Pascal DauphinHendersonville$925K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.